National statistics data show that Denmark’s GDP experienced a surge of 1.7% year-on-year during the first half of this year. However, a closer look reveals a crucial contributor to this growth – the pharmaceutical industry, without which the nation’s economy would have contracted by 0.3%.
Novo Nordisk, Denmark’s pharmaceutical powerhouse and — as of September — Europe’s largest entity by market capitalization, has played a pivotal role in this economic transformation. The company’s success can be attributed to the skyrocketing demand for anti-obesity drugs, driven by two flagship products: the widely popular anti-diabetic medication Ozempic, and the anti-obesity drug Wegovy.
Jonas Petersen, an analyst at Statistics Denmark, expressed his astonishment, stating, “We’ve never seen anything like it; it changes the appearance of the economy.” Novo Nordisk’s performance has not only bolstered government revenues but has also had a positive impact on employment rates and shareholder profits.
Sponsored · Selkirk Copper Mines
It changed the appearance of the economy so much that the country had to publish GDP data that did not include Novo Nordisk.
An X user points out that a similar phenomenon occurred in Ireland in 1998 when the sales of the impotence drug Viagra boosted the country’s GDP to “unbelievable” levels.
Novo Nordisk saw a 157% increase in sales of anti-obesity treatments during the first half of this year. These results have prompted Novo Nordisk to revise its forecasts, with sales expected to surge by 30% in 2023, following its 2022 sales of 176.95 billion kroner (US$16.51 billion).
RELATED: Not Just Inflation: People Are Buying Less Food, Joe Weisenthal Suggests Ozempic May Be to Blame
The company’s market capitalization has now surpassed 2,984 billion kroner (over US$421 billion), exceeding Denmark’s GDP, which stood at 2,832 billion kroner (US$398.3 billion) last year.
As mentioned earlier, on September 1st, the company surpassed the market capitalization of LVMH, a global luxury goods giant, making it the largest listed company in Europe, a position held by the French conglomerate for over two and a half years.
Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
